OA11.03 Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1-49% or ≥50%

T.J.N. Hiltermann, Hiroki Izumi, B.C. Cho, Sara Bernardes da Cunha, Pongwut Danchaivijitr, E. Felip, Gwo Fuang Ho, K. Leventakos, Yongsheng Li, S. Sugawara, P.J. Voon, Els Wauters, Tianpeng Yang, Mariana Brandão, H. Chen, Ikbel Achour, Steve Colebrook, Kiyoaki Sone, Nizar Bhulani, Djuro Karanovic, Y. Wang